Journal Information
Statistics
Follow this link to access the full text of the article
Original Article
Radioimmunotherapy for non-Hodgkin's lymphoma: positioning, safety, and efficacy of 90Y-ibritumomab. 10 years of experience and follow-up
Radioinmunoterapia en el linfoma no Hodgkin: posicionamiento, seguridad y eficacia de 90Y-ibritumomab. Experiencia y seguimiento a los 10 años